Argenx's Celiac Disease Phase 2 Study Meets Primary Endpoint; Discontinues Sjögren's UNITY Trial
Argenx reported positive Phase 2 results for FB102 in celiac disease, meeting its primary endpoint. The company will advance FB102 into Phase 3. Separately, argenx discontinued the Phase 3 UNITY study of efgartigimod in Sjögren's disease due to futility. Shares fell 7.91% overnight.
How this was made
The 30-second read
Why it matters
The mixed news triggered a 7.9% drop in ARGX shares, reflecting investor concern over the discontinued trial despite the positive celiac data.
Market read
The announcement provides fresh clinical trial data that can move ARGX stock and influences sentiment toward similar autoimmune biotech stocks.
What to watch
Potential for the company to redirect resources to other pipeline candidates and the existing approved indications for efgartigimod.
Background
argenx SE (NASDAQ:ARGX) announced successful Phase 2 results for its anti‑CD122 antibody FB102 in celiac disease and the termination of the Phase 3 UNITY study of efgartigimod in Sjögren's disease.
Ticker impact
Phase 2 FB102 trial met primary endpoint; UNITY Phase 3 discontinued; shares fell 7.9% overnight.
downward pressure as market prices in the discontinuation of the UNITY study despite positive celiac data
Positive celiac data is offset by the futility stop of the Sjögren's trial, leading to a net sell-off.
Market effects
May affect other biotech firms with autoimmune pipelines as investors reassess risk of FcRn-targeted therapies.
Limited to US and European biotech markets where ARGX is listed.
Modest; primarily relevant to specialty pharma investors.
Counterpoint
The positive celiac Phase 2 result could be a catalyst for long positions if the market overreacts to the UNITY discontinuation.
Key entities
- companyargenx SE
Immunology biotech developing antibody therapies.
- drug_candidateFB102
Anti‑CD122 antibody for celiac disease.
- drug_candidateefgartimod (VYVGART)
FcRn‑targeted antibody for autoimmune diseases.
